Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Latigo Biotherapeutics Inc.
Headquarters: Thousand Oaks, CA, United States of America
Website: https://latigobio.com/
Year Founded: 2018
Status: Private
BioCentury | Mar 21, 2025
Finance
Maxion, Ampersand, Latigo, Arbor raise private rounds: Finance Report
Plus: SV Health Investors hits $250M goal for second Dementia Discovery Fund
BioCentury | Nov 20, 2024
Management Tracks
Latigo names Timothy Walbert chair
Plus: Heather Turner to lead neurology play LB, and updates from Mirai Bio and Diakonos
BioCentury | Oct 3, 2024
Finance
Kurma investing new fund; Kailera advancing obesity assets with $400M
BioCentury’s latest Venture Report also features news about LoQus23, Aktis, Resolution, Triveni, Flagship and more
BioCentury | Sep 10, 2024
Management Tracks
Lucas Montarce named Lilly CFO
Plus: Yong Ben hired as chief medical and development officer of TheRas, and updates from Orbital, Latigo, AAVantgarde and more
BioCentury | Aug 19, 2024
Management Tracks
New commercial, regulatory heads at Fulcrum
Plus: Tiziana names Ivor Elrifi CEO, and updates from Soleno, Latigo, Fog and
BioCentury | Jul 22, 2024
Management Tracks
Nima Farzan named CEO of Latigo
Plus: Wu Changxiong succeeds Zhou Hua as CFO of Walvax, and updates from Hookipa, Janux, Akeso and Serina
BioCentury | Jun 14, 2024
Finance
How Foresite is investing its $900M fund during the ‘first era’ of AI-driven R&D
Weeks after the firm co-led Xaira’s $1B round, Michael Rome looks ahead at ‘big themes’
BioCentury | May 23, 2024
Emerging Company Profile
Halia: Leveraging RAB10 as a new lens on the NLRP3 inflammasome
Guided by human variation in the GTPase RAB10, Utah-based company seeks to disrupt inflammasome assembly
BioCentury | Mar 27, 2024
Emerging Company Profile
Latigo: aiming for best-in-class non-opioid analgesia via Nav1.8
Ex-Amgen executives reunite for CNS company incubated by Westlake and backed with $135M
BioCentury | Feb 16, 2024
Finance
Venture report: Earlybird’s €173M fund, launches for Firefly and Latigo
European VC closes new vehicle; start-ups backed by Versant, Westlake Village out of stealth; Medicxi’s bundle; rounds for Freenome, ProfoundBio
Items per page:
1 - 10 of 10